LeMaitre Vascular, Inc. Aktie News

LeMaitre Vascular remains a long-term compounder, delivering strong Q2 results with 15% sales growth, robust margins, and increased dividends. LMAT's investment thesis is supported by pricing power, an expanding product pipeline, disciplined capital allocation, and consistent reinvestment driving high returns on capital. Valuation is fair-to-full at current levels, with a $110-$111 price target...

BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences.

LeMaitre (LMAT) Q2 Revenue Jumps 15%

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants David B. Roberts - President & Director Dorian LeBlanc - Chief Financial Officer George W.

BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.

BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

We avoid very high-yielding stocks, as the best way to grow richer over time is to own a diversified basket of dividend growth stocks. Today, we're highlighting a leading alternative asset manager, a niche medical devices company, and Michigan's largest regulated utility. Relative to our fair value estimates, the trio of fast-growing businesses are trading at 4% to 7% discounts.

LeMaitre's revenue and earnings continue to grow, though profit growth has moderated. The European launch of Artegraft and pending approval of XenoSure in China are key near-term catalysts. The portfolio's increasing share of biologic products combined with operational improvements are supporting high margins.